Shares of Eagle Pharmaceuticals EGRX remained unaffected after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 71.43% year over year to $0.24, which missed the estimate of $0.65.
Revenue of $41,249,000 decreased by 10.37% from the same period last year, which missed the estimate of $45,410,000.
Guidance
Eagle Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 10, 2021
Time: 08:30 AM
Price Action
Company's 52-week high was at $56.16
Company's 52-week low was at $36.48
Price action over last quarter: Up 3.30%
Company Profile
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.